Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc C Gittelman

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
BJU International|August 20, 2011
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancerNeal Shore, Michael S Cookson, Marc C Gittelman
Open Access Journal of Urology|November 8, 2013
Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studiesMarc C Gittelman, Leonard S Marks, Lawrence A Hill, et al.
The Journal of Urology|April 18, 2009
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
Urology|October 10, 2009
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension studyLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
The Journal of Urology|December 14, 2012
Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
Urology Practice|June 10, 2023
Are Over-the-Counter Alpha Blockers in the Best Interest of Men with Lower Urinary Tract Symptoms?Claus G Roehrborn, Christian Gratzke, Kevin T McVary, et al.
Urology|August 2, 2003
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinenceRoger R Dmochowski, Peter K Sand, Norman R Zinner, et al.
The Journal of Urology|July 20, 2002
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinenceRoger R Dmochowski, G Willy Davila, Norman R Zinner, et al.
The Journal of Urology|February 19, 2013
PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical studyMarc C Gittelman, Bernard Hertzman, James Bailen, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2020
A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal MenRonald S Swerdloff, Christina Wang, William B White, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
BJU International|August 20, 2011
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancerNeal Shore, Michael S Cookson, Marc C Gittelman
Open Access Journal of Urology|November 8, 2013
Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studiesMarc C Gittelman, Leonard S Marks, Lawrence A Hill, et al.
The Journal of Urology|April 18, 2009
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
Urology|October 10, 2009
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension studyLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
The Journal of Urology|December 14, 2012
Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks, Marc C Gittelman, Lawrence A Hill, et al.
Urology Practice|June 10, 2023
Are Over-the-Counter Alpha Blockers in the Best Interest of Men with Lower Urinary Tract Symptoms?Claus G Roehrborn, Christian Gratzke, Kevin T McVary, et al.
Urology|August 2, 2003
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinenceRoger R Dmochowski, Peter K Sand, Norman R Zinner, et al.
The Journal of Urology|July 20, 2002
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinenceRoger R Dmochowski, G Willy Davila, Norman R Zinner, et al.
The Journal of Urology|February 19, 2013
PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical studyMarc C Gittelman, Bernard Hertzman, James Bailen, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2020
A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal MenRonald S Swerdloff, Christina Wang, William B White, et al.
Pageof 2